KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $10.7 million.

  • Halozyme Therapeutics' Capital Expenditures rose 99.74% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 16.06%. This contributed to the annual value of $10.7 million for FY2024, which is 30.06% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Capital Expenditures of $10.7 million as of FY2024, which was down 30.06% from $15.3 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Capital Expenditures high stood at $15.3 million for FY2023, and its period low was $1.5 million during FY2021.
  • Over the past 3 years, Halozyme Therapeutics' median Capital Expenditures value was $10.7 million (recorded in 2024), while the average stood at $10.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first slumped by 41.81% in 2021, then soared by 327.52% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Capital Expenditures (Yearly) stood at $2.5 million in 2020, then crashed by 41.81% to $1.5 million in 2021, then skyrocketed by 327.52% to $6.2 million in 2022, then soared by 145.53% to $15.3 million in 2023, then plummeted by 30.06% to $10.7 million in 2024.